^
    The Pan-cancer oncoReveal™ CDx is developed for tumor profiling and therapy selection, and includes actionable targets on ten of the most common cancer types. The panel provides comprehensive genomic results, covering 22 clinically relevant genes in one multiplex reaction, and has a fully automatable workflow that can be performed by any clinical laboratory with a sample-to-report time of as little as 48 hours.
    Cancer:
    Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
    Method:
    Next-Generation Sequencing (NGS)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    04/23/24
    ST
    -
    FDA